Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

AskBio

Biotech & Life Sciences · Durham, United States · Founded 2001 Unicorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$2.5–5B
Latest valuation · 2026
Unlock exact value
Headcount
500–1k
Current team size
Unlock exact value

Investors

2 investors on AskBio's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series B+ 2 investors entered at this stage

Global footprint

Where AskBio has talent and traffic

AI talent share
0.8% of workforce is AI talent
(4 of 505 staff)
Core AI10.2%
Other AI30.59%
Non-AI workforce50199.21%
Web traffic by country
16K monthly visits
across markets
🇺🇸 United States55%
🇬🇧 United Kingdom20%
🇮🇳 India12.5%
🇯🇵 Japan5%
🇪🇸 Spain5%
Top 5 markets shown

Patent intelligence

$14M patent portfolio · 42 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with topic prominence vs same-sector peers.

Estimated portfolio value
$14M
0.35% of valuation · 16.1× smaller than top peer Arvinas ($223M)
42 active patent families
Where AskBio innovates Heart failureDrugEnergy reservesProtein expressionHomeostasis

Tech-focus vs peers

Where AskBio concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across AskBio and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See AskBio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.